| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Liminatus Pharma, Inc.
13D
LIMN · 53271X108
|
26.5% |
5/8/2025
Event 4/30/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.